The Necessity of Enhanced Harm Reduction Programs to Prevent Blood-Borne Infections Amongst Injection Drug Users

Miri-Bonjar, Mahmodreza; Khorram, Alireza; Ansari‐Moghaddam, Alireza

doi:10.5812/jhealthscope.55868

Cited by 1 publication

(1 citation statement)

References 8 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most youth are unaware of the risk of acquiring HCV from drug use. Needle exchange programs can reduce the risk of infection ( 17 ). Hepatitis C treatment programs and intensive community-based education programs will remain the mainstays of HCV prevention ( 18 ).…”

Section: Contextmentioning

confidence: 99%

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline

et al. 2016

View full text Add to dashboard Cite

ContextHepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have changed the landscape of HCV treatment. This guideline provides updated recommendations for clinical management of HCV infection in Iran.Evidence AcquisitionThe recommendations of this guideline are based on international and national scientific evidences and consensus-based expert opinion. Scientific evidences were collected through a systematic review of studies that evaluated efficacy and safety of DAA regimens, using PubMed, Scopus and Web of Science. Expert opinion was based on the consensus of Iran Hepatitis Scientific Board (IHSB) in the 3rd national consensus on management of Hepatitis C in Iran, held on 22nd of July 2016.ResultsPegylated Interferon alpha (PegIFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV) and Daclatasvir (DCV) are currently available in Iran. Pre-treatment assessments include HCV RNA level, HCV genotype and resistance testing, assessment of liver fibrosis, and underlying diseases. In HCV genotype 1 and 4, DCV/SOF and LDV/SOF are recommended. In HCV genotype 2, SOF plus RBV and in HCV genotype 3, DCV/SOF is recommended. Additional care for underlying diseases should be considered.ConclusionsAffordable new HCV treatment regimens are available in Iran, providing an opportunity for HCV elimination. Recommendations provided in this current national guideline can facilitate evidence-based management of HCV infection.

show abstract

Section: Contextmentioning

confidence: 99%